<DOC>
	<DOCNO>NCT01108913</DOCNO>
	<brief_summary>The purpose study determine whether inhalation Bimosiamose safe effective treatment patient moderate severe Chronic Obstructive Pulmonary Disease ( COPD )</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Inhaled Bimosiamose Treatment Patients With Moderate Severe Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Male postmenopausal sterile female patient history moderate severe COPD define Global Initiative Chronic Obstructive Lung Disease ( GOLD ) IIIII least 1 year At least 40 year age Current smoker exsmoker least 10 packyear smoke history ( Ten packyears define 20 cigarette day 10 year , 10 cigarette day 20 year etc . ) Postbronchodilator FEV1 30 % 80 % predict FEV1/FVC ratio &lt; 70 % . Postbronchodilator refer 30 min inhalation 400 µg Salbutamol . This criterion FEV1 demonstrate washout period least 48 h long act anticholinergic medication ( LAMA ) long act β2agonists ( LABA ) inhale washout period 6 h short act β2agonists ( SABA ) anticholinergic medication ( SAMA ) inhale . For patient pretreated inhaled corticosteroid ( ICS ) and/or theophylline , criterion need demonstrate washout least 4 week . Able produce sputum upon induction sufficient quality . This criterion check responsible sputum lab prior randomization patient . Time ability complete study Able communicate well investigator , understand comply requirement study . Understand sign write informed consent . Patients history chronic respiratory disorder COPD e.g . asthma , α1Antitrypsin deficiency , mucoviscidosis , lung fibrosis Patients experience exacerbation 4 week screen visit screen randomization Patients experience acute upper respiratory tract infection bronchopulmonary infection require antibiotic treatment 4 week screen visit screen randomization Treatment inhale ( ICS ) , topical systemic corticosteroid theophylline within least 4 week screen visit throughout entire course study . Patients ICS and/or theophylline treatment undergo washout least 4 week signature inform consent prior screen visit , eligibility enter study assess</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>COPD</keyword>
</DOC>